Leishmaniasis, also known as white leprosy, is a tropical disease caused by protozoan parasites of the genus Leishmania. The disease presents itself in three main forms: cutaneous, mucocutaneous, and visceral leishmaniasis. Treatment options for leishmaniasis include pentavalent antimonials, miltefosine, and amphotericin B. Several drug manufacturers are investing in research and development to introduce new treatment options for leishmaniasis. The global Leishmaniasis Treatment Market is estimated to be valued at US$ 79.95 billion in 2023 and is expected to exhibit a CAGR of 22% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Rise in new product launches: The Global Leishmaniasis Treatment Market Size has witnessed several new product launches recently, which is one of the key trends in the market. In 2021, Sarepta Therapeutics, Inc. received Breakthrough Therapy designation from the U.S. Food and Drug Administration for SRP-9001 for the treatment of ambulatory patients with Leishmaniasis. SRP-9001 is designed to provide immune-mediated clearance of Leishmania parasites and reduce the treatment burden compared to current treatment options. Such new product developments are expected to drive the market growth over the forecast period.
Strength: The leishmaniasis treatment market possesses strong product pipeline with drugs in late stages of clinical trials which can drive market growth. Promising clinical trial results of new therapies can capture significant market share.
Weakness: High cost of R&D and reluctance of pharmaceutical companies to invest in neglected tropical diseases act as weakness for this market. The treatment market is also fragmented with small player base.
Opportunity: Rise in leishmaniasis disease incidence globally especially in developing nations acts as an opportunity. Government funding and initiatives to develop new treatment offer opportunities. Growing contract research and manufacturing services also open opportunities.
Threats: Stringent regulatory requirements for approval of drugs remains primary threat. Other threats include unreliable funding and supply issues in endemic regions. Patent expiries of blockbuster drugs also pose threat to existing players.
The global leishmaniasis treatment market is expected to witness high growth. The market size for 2024 is estimated at US$ 79.95 billion showing strong growth potential over the forecast period.
Regional analysis – The Asia Pacific region currently dominates the market and is anticipated to grow at fastest CAGR during the forecast period. Countries like India, Brazil witness highest leishmaniasis disease burden driving significant market growth. Europe and North America also capture sizable market share due to supportive regulatory environment and higher adoption.
Key players operating in the leishmaniasis treatment market are Johnson & Johnson, Intrabio, Cyclo Therapeutics, Inc., Kempharm, Inc., Azafaros B.V., StrideBio. Sarepta Therapeutics, Inc. The market is moderately consolidated with few big pharmaceutical companies dominating. Johnson & Johnson leads with its antimonial sodium stibogluconate injection brand. The other global companies focus on drug development through collaborations to strengthen their product pipelines.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it